Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964153 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2SLC6A4SLC6A3HSD11B1HRH3 | |
| SCHEMBL5963919 | 0.84 | NR1H2 (0.34) | SLC6A4SLC6A3KMT2ASLC6A2GRIN1 | |
| SCHEMBL5964157 | 0.82 | SLC6A2 (0.36) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5963352 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5964124 | 0.77 | LMNA (0.33) | SLC6A4SLC6A3HSD11B1SLC6A2 | |
| SCHEMBL5964630 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5963669 | 0.67 | CHRNB2 (0.37) | SLC6A4SLC6A3HSD11B1SLC6A2 | |
| SCHEMBL5963809 | 0.66 | LMNA (0.36) | SMN1; SMN2SLC6A4KMT2A | |
| SCHEMBL5963426 | 0.65 | SLC6A2 (0.36) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5964235 | 0.63 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | SMN1; SMN2 3213/4885SLC6A4 794/4885SLC6A3 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.